Pfizer and GSK to form HIV specialty company

Share this article:

Pfizer and GlaxoSmithKline will combine their HIV products and pipelines to form a specialty company, according to an announcement today.

The business, focused solely on research, development and commercialization of HIV medicines, will capture 19% of the category's global market share, the statement said. Initially, GSK will hold an 85% interest in the company, with Pfizer at 15%.

“At the core of this specialist business is a broad portfolio of products and pipeline assets, which can be more effectively leveraged through the new company's strong revenue base and dedicated research capability,” said Andrew Witty, GSK's CEO, in the statement.

Jeff Kindler, CEO at Pfizer, said: “With the strength of the companies' current HIV products, as well as the complementary fit of Pfizer's HIV pipeline and GSK's global distribution capabilities, the new company is well positioned to bring new and improved medicines to patients with more speed and efficiency.”

The combined company portfolio contains 11 marketed products – including top GSK sellers Combivir and Epzicom, and Pfizer's Selzentry – with an additional six products in the early phases of development. Combivir is the fifth best-selling drug in the US, with $409.4 million in sales for 2008, according to IMS Health data. Bristol-Myers Squibb and Gilead's combination therapy Atripla leads the category at $1.4 billion in US sales for 2008, with Gilead's Truvada ($1.1 billion) in second and Bristol-Myers Squibb's Reyataz ($777.4 million) in third. The total US market for HIV drugs grew by 13% from 2007 ($6.4 billion) to 2008 ($7.2 billion).

Dominique Limet, currently SVP and head of GSK's personalized medicine strategy, has been appointed as CEO designate of the new company, and will become a member of the board. According to a Wall Street Journal report, the company could be worth as much as $7.5 billion.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...